Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fasudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 8/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 7/20 | 1.00 |
| ▸ | CCR2 | P41597 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.98 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.98 |
| ▸ | PRKD1 | Q15139 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.98 |
| ▸ | PRKCG | P05129 | 5/20 | 0.98 |
| ▸ | PRKCB | P05771 | 5/20 | 0.98 |
| ▸ | PRKCA | P17252 | 5/20 | 0.98 |
| ▸ | PRKCH | P24723 | 5/20 | 0.98 |
| ▸ | PRKCI | P41743 | 5/20 | 0.98 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.98 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.98 |
| ▸ | PRKACA | P17612 | 4/20 | 0.98 |
| ▸ | PRKACG | P22612 | 4/20 | 0.98 |
| ▸ | PRKACB | P22694 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fasudil SCHEMBL29351490 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL599053 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL29393852 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL30084458 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL6032335 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL30064396 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL6269513 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL4728659 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL4725334 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL2154690 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2784 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144819-A1 | NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives Thereof | IMMUNITYBIO, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4739323-A1 | <SMALLCAPS/>? ? ?EX VIVO? ? ? ? ?GENERATION OF IMMUNE EFFECTOR CELLS FROM APHERESIS MATERIAL INTERMEDIATES | ImmunityBio, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260097083-A1 | METHOD FOR PRODUCING PANCREATIC ENDODERM CELLS | KYOTO UNIVERSITY (JP) | 2026-04-09 | — | — | US | claimed |
| US-20260014167-A1 | Treating Amyotrophic Lateral Sclerosis Having Onset 24 Months Prior to Treatment | WOOLSEY PHARMACEUTICALS, INC. (US) | 2026-01-15 | — | — | US | claimed |
| EP-4678241-A2 | A QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR OR A CYTOKINE, AND CHIMERIC ANTIGEN RECEPTOR FOR GENETIC MODIFICATION OF IMMUNOTHERAPIES | ImmunityBio, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-12473347-B2 | Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells | IMMUNITYBIO, INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-12473348-B2 | Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells | IMMUNITYBIO, INC. (US) | 2025-11-18 | — | — | US | claimed |
| EP-4629995-A1 | COMBINATION THERAPY FOR THE TREATMENT OF GLYOBLASTOMA | The University of Florida Research Foundation, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-12398370-B2 | Culture medium and method for inducing iPSC differentiation to obtain macrophages and use thereof | ALLIFE MEDICINE (BEIJING) LIMITED (CN) | 2025-08-26 | — | — | US | claimed |
| EP-4601636-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS BY ORAL ADMINISTRATION OF FASUDIL | Woolsey Pharmaceuticals, Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| WO-2004003170-A2 | AGENTS CAPABLE OF INHIBITING RAS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2004-01-08 | — | — | WO | claimed |
| US-20030139801-A1 | Delivery of therapeutic capable agents | AVANTEC VASCULAR CORPORATION (US) | 2003-07-24 | — | — | US | claimed |
| US-20030050692-A1 | Delivery of therapeutic capable agents | AVANTEC VASCULAR CORPORATION | 2003-03-13 | — | — | US | claimed |
| WO-2003009779-A2 | DELIVERY OF THERAPEUTIC CAPABLE AGENTS | AVANTEC VASCULAR CORPORATION (US) | 2003-02-06 | — | — | WO | claimed |
| WO-2003009777-A2 | DELIVERY OF THERAPEUTIC CAPABLE AGENTS | AVANTEC VASCULAR CORPORATION (US) | 2003-02-06 | — | — | WO | claimed |
| CN-1307476-A | Sustained release oral preparations of fasudil hydrochloride | ASAHI CHEMICAL IND (JP) | 2001-08-08 | — | — | CN | claimed |
| EP-1110553-A1 | SUSTAINED RELEASE ORAL PREPARATIONS OF FASUDIL HYDROCHLORIDE | Asahi Kasei Kabushiki Kaisha (JP) | 2001-06-27 | — | — | EP | claimed |
| EP-1064944-A1 | Protein kinase N inhibitor comprising Fasudil | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-01-03 | — | — | EP | claimed |
| EP-0845265-A1 | MUCOSAL PREPARATION CONTAINING PHYSIOLOGICALLY ACTIVE PEPTIDE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-06-03 | — | — | EP | claimed |
| EP-0003069-A1 | Pseudomonic acid C, pharmaceutically acceptable salts or esters thereof, processes for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1979-07-25 | — | — | EP | claimed |